Literature DB >> 29725946

Spectrophotometric photodynamic diagnosis of prostate cancer cells excreted in voided urine using 5-aminolevulinic acid.

Yasushi Nakai1, Makito Miyake1, Satoshi Anai1, Shunta Hori1, Yoshihiro Tatsumi1, Yosuke Morizawa1, Sayuri Onisi1, Nobumichi Tanaka1, Kiyohide Fujimoto2.   

Abstract

To evaluate the feasibility of photodynamic diagnosis using 5-aminolevulinic acid (PDD-ALA) for detection of prostate cancer (PCa) cells in urine samples after prostate massage in patients who were suspected to have PCa. One hundred and eighty-nine patients with abnormal digital rectal examination and/or an elevated prostate-specific antigen (PSA) level who underwent initial prostate biopsy were recruited. After prostate massage, the first 60 mL of voided urine was collected. For PDD-ALA, 50 mL was used. The rest of collected urine was used for polymerase chain reaction (PCR) of PSA and glyceraldehyde 3-phosphate dehydrogenase (GAPDH). After incubation for 2 h, the intensity was measured at 635 nm under a 405-nm wavelength excitation. The results of PDD-ALA were compared with those of an initial transrectal ultrasound (TRUS)-guided prostate biopsy. Overall, 126/189 (67%) samples that showed bands of both PSA and GAPDH on PCR in urine samples were analyzed. The area under the curve, sensitivity, and specificity of PDD-ALA were 0.74, 77, and 67%, respectively. The value of PDD-ALA was significantly higher in patients with Gleason scores of 6 (p = 0.03), 7 (p = 0.005), and 8-10 (p = 0.0002) than in those with negative biopsy results. In the multivariate analysis, high PSA density, abnormal findings on TRUS, and a high value of PDD-ALA were significant markers for prediction of positive biopsy results. PDD-ALA was useful to predict positive biopsy results in patients who underwent initial prostate biopsy with suspected PCa. This PCa-detection method has potential for clinical use.

Entities:  

Keywords:  5-aminolevulinic acid; Cytology; Initial prostate biopsy; Photodynamic diagnosis; Prostate cancer

Mesh:

Substances:

Year:  2018        PMID: 29725946     DOI: 10.1007/s10103-018-2519-4

Source DB:  PubMed          Journal:  Lasers Med Sci        ISSN: 0268-8921            Impact factor:   3.161


  34 in total

1.  [-2]Proenzyme prostate specific antigen is more accurate than total and free prostate specific antigen in differentiating prostate cancer from benign disease in a prospective prostate cancer screening study.

Authors:  Brian V Le; Christopher R Griffin; Stacy Loeb; Gustavo F Carvalhal; Donghui Kan; Nikola A Baumann; William J Catalona
Journal:  J Urol       Date:  2010-02-19       Impact factor: 7.450

2.  Clinical evaluation of the PCA3 assay in guiding initial biopsy decisions.

Authors:  Alexandre de la Taille; Jacques Irani; Markus Graefen; Felix Chun; Theo de Reijke; Paul Kil; Paolo Gontero; Alain Mottaz; Alexander Haese
Journal:  J Urol       Date:  2011-04-15       Impact factor: 7.450

3.  Hexyl aminolevulinate fluorescence cystoscopy: new diagnostic tool for photodiagnosis of superficial bladder cancer--a multicenter study.

Authors:  Patrice Jichlinski; Louis Guillou; Steinar J Karlsen; Per-Uno Malmström; Dieter Jocham; Bjørn Brennhovd; Eva Johansson; Thomas Gärtner; Norbert Lange; Hubert van den Bergh; Hans-Jürg Leisinger
Journal:  J Urol       Date:  2003-07       Impact factor: 7.450

4.  Free, complexed and total serum prostate specific antigen: the establishment of appropriate reference ranges for their concentrations and ratios.

Authors:  J E Oesterling; S J Jacobsen; G G Klee; K Pettersson; T Piironen; P A Abrahamsson; U H Stenman; B Dowell; T Lövgren; H Lilja
Journal:  J Urol       Date:  1995-09       Impact factor: 7.450

5.  Fluorescence confocal microscopy and image analysis of bladder cancer using 5-aminolevulinic acid.

Authors:  Malini Olivo; Weber Lau; Vanaja Manivasager; Tan Puay Hoon; Cheng Christopher
Journal:  Int J Oncol       Date:  2003-03       Impact factor: 5.650

6.  Correlation of prostate-specific antigen and prostate-specific antigen density with outcome of prostate biopsy.

Authors:  R Bare; L Hart; D L McCullough
Journal:  Urology       Date:  1994-02       Impact factor: 2.649

7.  [-2]proenzyme prostate specific antigen for prostate cancer detection: a national cancer institute early detection research network validation study.

Authors:  Lori J Sokoll; Yinghui Wang; Ziding Feng; Jacob Kagan; Alan W Partin; Martin G Sanda; Ian M Thompson; Daniel W Chan
Journal:  J Urol       Date:  2008-06-11       Impact factor: 7.450

8.  Clinical relevance of genetic instability in prostatic cells obtained by prostatic massage in early prostate cancer.

Authors:  R Thuret; K Chantrel-Groussard; A-R Azzouzi; J-M Villette; S Guimard; P Teillac; P Berthon; A Houlgatte; A Latil; O Cussenot
Journal:  Br J Cancer       Date:  2005-01-31       Impact factor: 7.640

9.  Rotterdam Prostate Cancer Risk Calculator: Development and Usability Testing of the Mobile Phone App.

Authors:  Nuno Pereira-Azevedo; Luís Osório; Avelino Fraga; Monique J Roobol
Journal:  JMIR Cancer       Date:  2017-01-06

10.  The optimal number of initial prostate biopsy cores in daily practice: a prospective study using the Nara Urological Research and Treatment Group nomogram.

Authors:  Nobumichi Tanaka; Keiji Shimada; Yoshinori Nakagawa; Shuya Hirao; Shuji Watanabe; Makito Miyake; Satoshi Anai; Akihide Hirayama; Noboru Konishi; Kiyohide Fujimoto
Journal:  BMC Res Notes       Date:  2015-11-18
View more
  1 in total

1.  Probing Hexaminolevulinate Mediated PpIX Fluorescence in Cancer Cell Suspensions in the Presence of Chemical Adjuvants.

Authors:  Kit Man Chan; Jonathan Gleadle; Krasimir Vasilev; Melanie MacGregor
Journal:  Int J Mol Sci       Date:  2020-04-22       Impact factor: 5.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.